|
| |
GENOME THERAPEUTICS: CASHING IN ON OSTEOPOROSIS.
hotcampusteens x nd17 xDate: 11 Dec 2007
Time: 18:48:25
Commentshttp://www.herfirstanalsex.com/?revid=28792
http://www.herfirstbigcock.com/?revid=28792
http://www.herfirstdp.com/?revid=28792
http://www.hisfirstfacial.com/?revid=28792
http://www.hisfirstgaysex.com/?revid=28792
http://www.hisfirsthugecock.com/?revid=28792
http://www.herfirstlesbiansex.com/?revid=28792
http://www.milfhunter.com/?id=chikenn
Date: 18 Jun 2001
Time: 09:46:16
Comments
The payments made by Wyeth-Ayerst to Genome Therapeutics (GENE) for the completion of a major advancement in their genomics-based alliance to develop novel therapeutics for the prevention and treatment of osteoporosis was expected. The accomplishments GENE made since it gained access to a unique family of individuals exhibiting a high bone mass trait from Creighton University in 1997 began to be appreciated
In the past couple of months, the firm has gathered more visibility as the news about the advancement made in its osteoporosis progrrams was heard.
Genome Therapeutics operates two lines of business: genomics services and biopharmaceutical. The genomics services business focuses on services that enable other organizations to achieve their drug discovery objectives and includes the GTC Sequencing Center and the PathoGenome(TM)Database.
The biopharmaceutical business focuses on the development of novel therapeutics, vaccines and diagnostics to solve major medical needs, includes six alliances with pharmaceutical companies (Schering-Plough, AstraZeneca, Wyeth-Ayerst and bioMerieux) and a joint venture with ArQule.
We are watching
|
Prohost is an independent publication providing information
on biotech companies. Prohost does not accept compensation from companies that are
featured or profiled. It is strongly recommended that any purchase or sale decisions to
any of the featured companies be discussed with a financial advisor or broker prior to
completing any such purchase or sale decision. All statements or expressions are the
opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell,
or hold securities. Investing in embryonic companies, micro-cap and growth securities is
highly speculative and carries a high degree of risk. It is possible that an investor can
lose all of his/her investment in this type of companies that are profiled. The
information that Prohost relies on is either through the profiled company, news services,
research reports, interviews, or other outside sources that Prohost believes are reliable.
Prohost makes no representations, warranties or guarantees as to the accuracy or
completeness of the disclosure of the profiled companies and accepts no responsibilities
for inaccuracies or misleading content in any material supplied by those clients. There
can be no assurance that future events relating to the profiled company will occur as
anticipated. The information contained herein is provided as an information service only.
Past performance of featured companies does not guarantee the future success of any
currently featured or profiled company. We encourage our readers to invest carefully and
read the investor information provided by the Securities and Exchange Commission
("SEC") and/or the National Association of Securities Dealers
("NASD"). We also strongly recommend that you read the SEC advisory to investors
concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.
Send mail to CompanyWebmaster with questions or comments about
this web site.
Copyright © 2001 CompanyLongName
|
|
